Filter Results:
(12)
Show Results For
- All HBS Web
(12)
- Research (11)
- Faculty Publications (2)
Show Results For
- All HBS Web
(12)
- Research (11)
- Faculty Publications (2)
Page 1 of 12
Results
- 26 Jul 2016
- Working Paper Summaries
The Impact of the Entry of Biosimilars: Evidence from Europe
- 29 Jan 2019
- First Look
New Research and Ideas, January 29, 2019
and Competitor Response: Evidence from Medical Device Firms By: Ball, George P., Jeffrey T. Macher, and Ariel Dora View Details
Keywords: Dina Gerdeman
- 14 Nov 2017
- First Look
New Research and Ideas: November 14, 2017
the Design and Execution of Medical Device Pivotal Trials By: Stern, Ariel Dora, and Aaron V. Kaplan Abstract—The introduction of new medical... View Details
Keywords: Carmen Nobel
- 20 Dec 2016
- First Look
December 20, 2016
to creating your own model. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=52002 January 2017 Journal of Public Economics Innovation Under Regulatory Uncertainty: Evidence from Medical Technology By: Stern, View Details
Keywords: Carmen Nobel
- 21 Aug 2018
- First Look
New Research and Ideas, August 21, 2018
best be applied. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=54809 August 2018 Review of Industrial Organization The Impact of the Entry of Biosimilars: Evidence from Europe By: Scott View Details
Keywords: Dina Gerdeman
- 18 Apr 2018
- First Look
First Look at New Research and Ideas, April 18, 2018
The Impact of the Entry of Biosimilars: Evidence from Europe By: Scott Morton, Fiona, Ariel Dora Stern, View Details
Keywords: Sean Silverthorne
- Web
Fostering Innovation in Life Sciences - Health Care
Evidence from Europe By: Fiona M. Scott Morton, Ariel Dora Stern View Details
- 09 Aug 2016
- First Look
August 9, 2016
https://www.hbs.edu/faculty/Pages/item.aspx?num=51304 The Impact of the Entry of Biosimilars: Evidence from Europe By: Scott Morton, Fiona, Ariel View Details
Keywords: Sean Silverthorne
- August 2018
- Article
The Impact of the Entry of Biosimilars: Evidence from Europe
By: Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern
Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby... View Details
Keywords: Health Care; Biosimilars; Biologics; Pharmaceutical Competition; Healthcare Spending; Innovation; Health Care and Treatment; Spending; Market Entry and Exit; Competition; Innovation and Invention; Pharmaceutical Industry; United States; Europe
Scott Morton, Fiona M., Ariel Dora Stern, and Scott Stern. "The Impact of the Entry of Biosimilars: Evidence from Europe." Review of Industrial Organization 53, no. 1 (August 2018): 173–210.
- 2018
- Other Unpublished Work
Online Appendix to the paper The Impact of the Entry of Biosimilars: Evidence from Europe
By: Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern
Scott Morton, Fiona M., Ariel Dora Stern, and Scott Stern. "Online Appendix to the paper The Impact of the Entry of Biosimilars: Evidence from Europe."